CAR T-cell therapy in multiple myeloma: mission accomplished?

2.

Hansen

DK

,

Sidana

S

,

Peres

LC

, et al.

Idecabtagene Vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium

.

J Clin Oncol

.

2023

;

41

(

11

):

2087

-

2097

.

3.

Munshi

NC

,

Anderson

LD

,

Shah

N

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

-

716

.

4.

Ferreri

CJ

,

Hildebrandt

MAT

,

Hashmi

H

, et al.

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

.

Blood Cancer J

.

2023

;

13

(

1

):

117

.

5.

Moreau

P

,

Garfall

AL

,

van de Donk

N

, et al.

Teclistamab in relapsed or refractory multiple myeloma

.

N Engl J Med

.

2022

;

387

(

6

):

495

-

505

.

6.

Lesokhin

AM

,

Tomasson

MH

,

Arnulf

B

, et al.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

.

Nat Med

.

2023

;

29

(

9

):

2259

-

2267

.

7.

Bahlis

NJ

,

Costello

CL

,

Raje

NS

, et al.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

.

Nat Med

.

2023

;

29

(

10

):

2570

-

2576

.

8.

Kegyes

D

,

Constantinescu

C

,

Vrancken

L

, et al.

Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?

.

J Hematol Oncol

.

2022

;

15

(

1

):

78

.

9.

Reyes

KR

,

Huang

CY

,

Lo

M

, et al.

Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma

.

Transplant Cell Ther

.

2023

;

29

(

6

):

350

-

355

.

10.

Wasch

R

,

Strussmann

T

,

Wehr

C

, et al.

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis

.

Ann Hematol

.

2023

;

102

(

5

):

1269

-

1270

.

11.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

-

324

.

12.

Prommersberger

S

,

Reiser

M

,

Beckmann

J

, et al.

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

.

Gene Ther

.

2021

;

28

(

9

):

560

-

571

.

13.

Mailankody

S

,

Matous

JV

,

Chhabra

S

, et al.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

.

Nat Med

.

2023

;

29

(

2

):

422

-

429

.

14.

Zhou

X

,

Rasche

L

,

Kortum

KM

,

Danhof

S

,

Hudecek

M

,

Einsele

H

.

Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies

.

Front Immunol

.

2020

;

11

:

620312

.

15.

Hayden

PJ

,

Roddie

C

,

Bader

P

, et al.

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

.

Ann Oncol

.

2022

;

33

(

3

):

259

-

275

.

16.

Kennedy

VE

,

Wong

C

,

Huang

CY

, et al.

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma

.

Blood Adv

.

2021

;

5

(

23

):

5344

-

5348

.

17.

Giavridis

T

,

van der Stegen

SJC

,

Eyquem

J

,

Hamieh

M

,

Piersigilli

A

,

Sadelain

M

.

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

.

Nat Med

.

2018

;

24

(

6

):

731

-

738

.

18.

Leipold

AM

,

Werner

RA

,

Dull

J

, et al.

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

.

Leukemia

.

2023

;

37

(

3

):

650

-

658

.

19.

de Boer

JW

,

Pennings

ERA

,

Kleinjan

A

, et al.

Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

.

Blood Adv

.

2023;7(21):6710-6716

.

20.

Diaz-Tejedor

A

,

Lorenzo-Mohamed

M

,

Puig

N

, et al.

Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression

.

Cancers (Basel)

.

2021

;

13

(

6

):

1353

.

21.

Attal

M

,

Lauwers-Cances

V

,

Hulin

C

, et al.

Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma

.

N Engl J Med

.

2017

;

376

(

14

):

1311

-

1320

.

22.

Mohan

M

,

Nagavally

S

,

Dhakal

B

, et al.

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma

.

Blood Adv

.

2022

;

6

(

8

):

2466

-

2470

.

23.

Wang

Y

,

Li

C

,

Xia

J

, et al.

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

.

Blood Adv

.

2021

;

5

(

23

):

5290

-

5299

.

24.

Sharma

N

,

Reagan

PM

,

Liesveld

JL

.

Cytopenia after CAR-T cell therapy—a brief review of a complex problem

.

Cancers (Basel)

.

2022

;

14

(

6

):

1501

.

25.

Rejeski

K

,

Hansen

DK

,

Bansal

R

, et al.

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

.

J Hematol Oncol

.

2023

;

16

(

1

):

88

.

26.

Mullanfiroze

K

,

Lazareva

A

,

Chu

J

, et al.

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

16

):

4715

-

4718

.

27.

Jain

T

,

Olson

TS

,

Locke

FL

.

How I treat cytopenias after CAR T-cell therapy

.

Blood

.

2023

;

141

(

20

):

2460

-

2469

.

28.

Cohen

AD

,

Parekh

S

,

Santomasso

BD

, et al.

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

.

Blood Cancer J

.

2022

;

12

(

2

):

32

.

29.

Van Oekelen

O

,

Aleman

A

,

Upadhyaya

B

, et al.

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

.

Nat Med

.

2021

;

27

(

12

):

2099

-

2103

.

30.

Graham

CE

,

Lee

WH

,

Wiggin

HR

, et al.

Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity

.

Blood

.

2023

;

142

(

14

):

1248

-

1252

.

31.

Hansen

DK

,

Patel

KK

,

Peres

LC

, et al.

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

8012

.

32.

Lakshman

A

,

Singh

PP

,

Rajkumar

SV

, et al.

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

.

Am J Hematol

.

2018

;

93

(

2

):

179

-

186

.

33.

Rasche

L

,

Strifler

S

,

Duell

J

, et al.

The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma

.

Ann Hematol

.

2014

;

93

(

7

):

1207

-

1214

.

34.

Zhou

X

,

Ruckdeschel

A

,

Peter

J

, et al.

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

.

Hematol Oncol

.

2022

;

40

(

2

):

202

-

211

.

35.

Mailankody

S

,

Devlin

SM

,

Landa

J

, et al.

GPRC5D-targeted CAR T cells for myeloma

.

N Engl J Med

.

2022

;

387

(

13

):

1196

-

1206

.

36.

Chari

A

,

Minnema

MC

,

Berdeja

JG

, et al.

Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma

.

N Engl J Med

.

2022

;

387

(

24

):

2232

-

2244

.

37.

Jiang

D

,

Huang

H

,

Qin

H

, et al.

Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

.

Nat Commun

.

2023

;

14

(

1

):

3642

.

38.

Gogishvili

T

,

Danhof

S

,

Prommersberger

S

, et al.

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes

.

Blood

.

2017

;

130

(

26

):

2838

-

2847

.

39.

Da Via

MC

,

Dietrich

O

,

Truger

M

, et al.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

.

Nat Med

.

2021

;

27

(

4

):

616

-

619

.

40.

Truger

MS

,

Duell

J

,

Zhou

X

, et al.

Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM

.

Blood Adv

.

2021

;

5

(

19

):

3794

-

3798

.

41.

Samur

MK

,

Fulciniti

M

,

Aktas Samur

A

, et al.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

.

Nat Commun

.

2021

;

12

(

1

):

868

.

42.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

.

Nat Med

.

2023

;

29

(

9

):

2295

-

2306

.

43.

Nerreter

T

,

Letschert

S

,

Gotz

R

, et al.

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

.

Nat Commun

.

2019

;

10

(

1

):

3137

.

44.

Spiegel

JY

,

Patel

S

,

Muffly

L

, et al.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

.

Nat Med

.

2021

;

27

(

8

):

1419

-

1431

.

45.

Lin

Y

,

Raje

NS

,

Berdeja

JG

, et al.

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

.

Nat Med

.

2023

;

29

(

9

):

2286

-

2294

.

46.

Lynn

RC

,

Weber

EW

,

Sotillo

E

, et al.

c-Jun overexpression in CAR T cells induces exhaustion resistance

.

Nature

.

2019

;

576

(

7786

):

293

-

300

.

47.

Ataide

MA

,

Komander

K

,

Knopper

K

, et al.

BATF3 programs CD8(+) T cell memory

.

Nat Immunol

.

2020

;

21

(

11

):

1397

-

1407

.

48.

Robinson

MH

,

Villa

NY

,

Jaye

DL

, et al.

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

.

J Clin Invest

.

2023

;

133

(

15

):

e167629

.

49.

John

L

,

Poos

AM

,

Brobeil

A

, et al.

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

.

Nat Commun

.

2023

;

14

(

1

):

5011

.

50.

Rodriguez-Otero

P

,

Ailawadhi

S

,

Arnulf

B

, et al.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2023

;

388

(

11

):

1002

-

1014

.

51.

San-Miguel

J

,

Dhakal

B

,

Yong

K

, et al.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

.

N Engl J Med

.

2023

;

389

(

4

):

335

-

347

.